Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients

Journal of Clinical Oncology

Volumn 18, Issue 21 SUPPL., 2000, Pages

  Verhoog, L C ^a   Berns, E M J J ^a   Brekelmans, C T M ^a   Seynaeve, C ^a   Meijers Heijboer, E J ^a   Klijn, J G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW;

BRCA2 PROTEIN; BREAST NEOPLASMS; FAMILY HEALTH; GERM-LINE MUTATION; HUMANS; MEDICAL HISTORY TAKING; NEOPLASM PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 0034331177     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. The genetic attributable risk of breast and ovarian cancer
2. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
3. Identification of the breast cancer susceptibility gene BRCA2
4. Survival in hereditary breast and colon cancer
5. Germline mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer
6. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
7. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
8. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 and BRCA2
9. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
10. The influence of familial and hereditary factors on the prognosis of breast cancer
11. Genetic analysis of cancer in families
12. Genetic and hormonal risk factors for breast cancer
13. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
14. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
15. Evidence for a third breastcancer susceptibility gene
16. Loss of heterozygosity and linkage analysis in breast carcinoma: Indication for a putative third susceptibility gene on the short arm of chromosome 8
17. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancersusceptibility genes?
18. BRCA1 mutations in a population-based sample of young women with breast cancer
19. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
20. Frequency of breast cancer attributable to BRCA in a population-based series of American women
21. Cancer risk with 185delAG and 5382insc mutations of BRCA1 and the 6174delT mutation of BRCA2 among Ashkenazi Jews
22. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
23. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
24. Stable interaction between the products of BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
25. BRCA1 mutations in primary breast and ovarian carcinomas
26. BRCA2 mutations in primary breast and ovarian cancers
27. Low incidence of BRCA2 mutations in breast carcinomas and other cancers
28. Mutation analysis in the BRCA2 gene in primary breast cancers
29. BRCA-associated breast cancer in young women
30. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
31. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
32. Oral contraceptives and the risk of hereditary ovarian cancer
33. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
34. Inherited BRCA2 mutation associated with high grade breast cancer
35. Steroid receptors in hereditary breast carcinomas associated with BRCA1 and BRCA2 mutations or unknown susceptibility genes
36. Survival in hereditary breast cancer associated with germline mutations of BRCA2
37. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
38. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P- 1 study
39. Pathobiological characteristics of hereditary breast cancer
40. Medullary carcinoma of the breast: A clinicopathologic study with 10 year follow-up
41. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population based study
42. An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy
43. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene
44. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
45. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
46. Prognosis and clinical presentation of BRCA2 associated breast cancer
47. Breast carcinomas in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
48. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
49. Haplo-type and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study
50. Survival of patients with breast cancer and BRCA1 mutations